Similar articles

• The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

  Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J. Milne RL, et al. Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436. Clin Cancer Res. 2008. PMID: 18451254
• One risk fits all?

  De Bock GH, Mourits MJ, Oosterwijk JC. De Bock GH, et al. J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. doi: 10.1200/JCO.2007.12.3489. J Clin Oncol. 2007. PMID: 17664491 No abstract available.
• Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

  Wolff TA, Wilson JE. Wolff TA, et al. Am Fam Physician. 2006 Nov 15;74(10):1759-60. Am Fam Physician. 2006. PMID: 17137007 Review. No abstract available.
• [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].

  Loman N. Loman N. Lakartidningen. 2004 Jun 17;101(25):2172-7. Lakartidningen. 2004. PMID: 15281304 Review. Swedish.
• Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.

  Spannuth WA, Thaker PH, Sood AK. Spannuth WA, et al. Am J Obstet Gynecol. 2007 Apr;196(4):e6-9. doi: 10.1016/j.ajog.2007.01.026. Am J Obstet Gynecol. 2007. PMID: 17403394